Baseline characteristics of trial participants
| All (n=31) | Cycling (n=8) | Weights (n=7) | Combined (n=8) | Stretching (n=8) | |
|---|---|---|---|---|---|
| Age* | 57.6 (49.2–75.1) | 66.9 (55.8–82.4) | 59.7 (45.9–81.4) | 60.3 (54.7–68.4) | 49.3 (43.0–62.3) |
| Sex (male) | 24 (77) | 8 (100) | 6 (86) | 3 (38) | 7 (88) |
| Time on HD (years) | 3.2 (1.7–4.4) | 3.7 (2.4–4.6) | 2.8 (2.0–4.0) | 2.9 (0.7–2.3) | 3.3 (1.2–6.2) |
| Ethnicity | |||||
| Caucasian | 19 (61) | 7 (88) | 3 (43) | 5 (63) | 4 (50) |
| Southeast Asian | 4 (13) | 1 (13) | 1 (14) | 1 (13) | 2 (25) |
| Aboriginal | 3 (10) | 0 | 2 (29) | 0 | 1 (13) |
| Other | 5 (16) | 0 | 1 (14) | 2 (25) | 1 (13) |
| Cause of ESRD | |||||
| Diabetes | 7 (22.6) | 2 (25) | 1 (14.3) | 2 (25) | 2 (25) |
| Glomerulonephritis | 10 (32.3) | 1 (12.5) | 5 (71.4) | 4 (50) | 0 |
| Hypertension | 1 (3.2) | 1 (12.5) | 0 | 0 | 0 |
| Polycystic kidney disease | 3 (9.7) | 1 (12.5) | 0 | 1 (12.5) | 1 (12.5) |
| Reflux/urological | 3 (9.7) | 1 (12.5) | 0 | 0 | 2 (25) |
| Other | 5 (16.1) | 2 (25) | 1 (14.3) | 0 | 2 (25) |
| Unknown | 2 (6.5) | 0 | 0 | 1 (12.5) | 1 (12.5) |
| BMI | 24.7 (21.6–29.9) | 23.6 (22.2–25.7) | 25.9 (24.6–29.9) | 25.3 (20.0–30.8) | 24.2 (20.4–33.8) |
| Diabetes | 15 (48) | 3 (38) | 3 (43) | 5 (63) | 4 (50) |
| Hypertension | 28 (90) | 8 (100) | 7 (100) | 7 (88) | 6 (75) |
| β blocker | 14 (45) | 4 (50) | 4 (57) | 3 (38) | 3 (38) |
| Coronary artery disease | 8 (26) | 4 (50) | 1 (14) | 2 (25) | 1 (13) |
| Heart failure | 7 (23) | 4 (50) | 3 (43) | 0 | 0 |
| QoL-PCS | 35±8 | 35±9 | 32±9 | 35±10 | 36±3 |
| Never exercise in leisure time | 12 (39) | 3 (38) | 4 (57) | 1 (13) | 4 (50) |
*Median (IQR interval); N with (%) or mean (±SD); totals do not always add to 100 due to rounding.
HD, haemodialysis; BMI, body mass index; ESRD, end-stage renal disease; QoL-PCS, quality of life-physical component summary.